Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UKResearch in context

Summary: Background: Patients with advanced or recurrent endometrial cancer have poor survival outcomes because effective treatment options remain limited. We investigated the efficacy and safety of cediranib plus weekly paclitaxel or olaparib versus weekly paclitaxel alone after prior platinum-bas...

Description complète

Détails bibliographiques

Auteurs principaux:	Robert D. Morgan, Catharine Porter, Cong Zhou, Rebecca Kristeleit, Sudha Desai, Ignacio Vazquez, Angela George, Gemma Eminowicz, Axel Walther, Adrian Franklin, Azmat H. Sadozye, Andrew Hughes, Louise Hanna, Rene Roux, Rosemary Lord, Rebecca Bowen, Joey Wood, Clara Sentamans, Ann White, Angela C. Casbard, Alys Humphrys, Jennifer B. Swettenham, Lisette S. Nixon, Richard Adams, Ruby Ray, Elena Brogden, Wendy E. Powell, Joanna Canham, Tracy M. Cox, Monica Narasimham, Helen Lowe, Leah Ensell, Mohammed Zubair, Karen Morris, Molly Glenister-Doyle, Ariadna Fuertes Gassio, Derrick Morgan, Dylan Broughton, Margherita Carucci, Phillip J. Monaghan, Jonathan Tugwood, Richard J. Edmondson, Caroline Dive, Gordon C. Jayson, Andrew R. Clamp
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2026-06-01
Collection:	EClinicalMedicine
Sujets:	Clinical trial Endometrial cancer Paclitaxel Cediranib Olaparib Plasma Tie2
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S2589537026002610
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!